APP and Alzheimer disease: When interpreting results from the transgenic model and translating these to human AD trials, care must be taken to acknowledge the caveat that there is considerable divergence between the APP/PS1 transgenic model and AD with regard to iron concentration, inflammatory response, and structural morphology associated with Aβ plaques.